The strategy of enantiomer patents of drugs

Drug Discovery Today

Volumn 15, Issue 5-6, 2010, Pages 163-170

  Agranat, Israel ^a   Wainschtein, Silvya R ^a  

^a HEBREW UNIVERSITY OF JERUSALEM   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHETAMINE; ARMODAFINIL; ATORVASTATIN; CITALOPRAM; CLOPIDOGREL; DEXIBUPROFEN; DEXMETHYLPHENIDATE; ESCITALOPRAM; ESOMEPRAZOLE; ESZOPICLONE; LEVALBUTEROL; LEVOCETIRIZINE; LEVODOPA; LEVOFLOXACIN; LEVONORGESTREL; NAPROXEN; NORGESTREL; OMEPRAZOLE; PENICILLAMINE; RAMIPRIL;

DRUG FORMULATION; DRUG INDUSTRY; DRUG LEGISLATION; DRUG MARKETING; DRUG RESEARCH; DRUG SOLUBILITY; DRUG STRUCTURE; DRUG SYNTHESIS; ENANTIOMER; JURISPRUDENCE; LAW SUIT; PATENT; RACEMIC MIXTURE; SHORT SURVEY; STEREOCHEMISTRY; STEREOISOMERISM;

DRUG APPROVAL; DRUG INDUSTRY; HUMANS; PATENTS AS TOPIC; PHARMACEUTICAL PREPARATIONS; STEREOISOMERISM;

EID: 77649237491     PISSN: 13596446     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.drudis.2010.01.007     Document Type: Short Survey

References (61)

1. IMS Health (2009), Top 15 Global Products 2008, 2008 Global Prescription Sales Information, Top-line Industry Data, Press Room, 22.04.2009; http://www.imshealth.com
2. Agranat I., et al. Putting chirality to work: the strategy of chiral switches. Nat. Rev. Drug Discov. 1 (2002) 753-768
3. Anonymous. Patent watch: a new twist on the chiral switch. Nat. Rev. Drug Discov. 2 (2003) 424
4. The Hatch-Waxman Act is the name commonly used to refer to the Drug Price Competition and Patent Term Restoration Act of 1984, Pub. L. No. 98-417, 98 Stat. 1585 (1984) [codified at 21 U.S.C. §§ 355, 360(cc) (2000), 35 U.S.C. §§ 156, 271, 282 (2000)], as amended by the Medicare Prescription Drug, Improvement, and Modernization Act of 2003, Pub. L. No. 108-173, 117 Stat. 2066 (2003), and Food and Drug Administration Amendments Act, PUBLIC LAW 110-85 - Sept. 27, 2007
5. In re I.G. Farbenindustrie A. G.'s Patents [1930] 47 R.P.C. 289-334 (02.04.1930)
6. Beecham Group Ltd. v. Bristol Laboratories International S.A. [1978] RPC 521-579 (H.L.) (26.10.1977)
7. Dupont (Witsiepe's) Application [1982] FRS 303-316 (H.L.) (18.02.1982)
8. Dr. Reddy's Laboratories (UK) Limited v Eli Lilly and Company Limited [2008] EWHC 2345 (Pat) (13.10.2008)
9. Dr. Reddy's Laboratories (UK) Limited v Eli Lilly and Company Limited [2009] EWCA Civ 1362 (18.12.2009)
10. Beecham Group Limited's (Amoxicillin) Application [1980] RPC 261-304 (CA) (19.07.1979)
11. Apotex Inc. v. Sanofi-Synthelabo Canada, Inc. 2008 SCC 61 (06.11.2008)
12. Lundbeck Canada Inc. v. Genpharm ULC and Ors 2009 FC 146 (25.02.2009)
13. Ranbaxy Australia Pty Ltd (ACN 110 781 826) v. Warner-Lambert Company LLC [2008] FCAFC 82 (28.05.2008)
14. H. Lundbeck A/S v. Generics (UK) Ltd & Ors [2008] EWCA Civ 311; [2008] RPC 19 (10.04.2008)
15. Enantiomers/Hoechst EPO/TBA (1988) T 296/87; OJ EPO 1990, 195 (30.08.1988)
16. In re May 574 F. 2d 1082 (CCPA 1978) (20.04.1978); 197 U.S.P.Q. 601
17. Pfizer Inc. v. Ranbaxy Labs Ltd. 405 F. Supp. 2d 495 (D. Del. 2005)
18. Enantiomers/Zeneca EPO/TBA (1999) T F1046/97 (02.12.1999)
19. Alfred E. Tiefenbacher GmbH and Centrafarm Services B.V. and Ratiopharm GmbH v. H. Lundbeck A/S, District Court of the Hague (2009) 312468/ HA ZA 08-1827 (08.04.2009)
20. H. Lundbeck A/S v. Alphapharm Pty Ltd [2009] FCAFC 70 (11.06.2009)
21. Generics (UK) Ltd v. Daiichi Pharmaceutical Co Ltd & Anor [2009] EWCA Civ 646 (02.07.2009)
22. Aventis Pharma Deutchland GMBH & King Pharmaceuticals, Inc. v. Lupin, LTD, CAFC 2006-1530 (11.09.2007). 499 F. 1293 (Fed. Cir. 2007)
23. Ortho-McNeil Pharmaceuticals, Inc. and Ors v. Mylan Laboratories, Inc. and Anor, 348 F. Supp.2d 713 (US District Court, N.D. West Virginia), 2004
24. Janssen-Ortho Inc. and Anor v. Novopharm Limited 2006 FC 1234 (23.12.2004)
25. Pfizer Canada Inc. v. Apotex Inc. 2008 FC 13 (04.01.2008)
26. Ranbaxy UK Limited. v. Warner-Lambert Company [2006] EWCA Civ 876, R.P.C. 4 (28.06.2006)
27. Angiotech Pharmaceuticals & Anr v. Conor Medsystems, Inc. [2007] EWCA Civ 5 [2007] RPC 20 (16.01.2007)
28. KSR International Co. v. Teleflex Inc. 550 U.S. 398 (2007); 127 S. Ct. 1717 (2007) (30.04.2007)
29. HARVARD/Fusion protein (1990) EPO/TBA T 0060/89; OJ EPO 1992, 268 (1992) EPOR 320 (31.08.1990)
30. Aktiebolaget Hassle v. Alphapharm Pty Ltd [2002] HCA 59; (2002) 212 CLR 411 (12.12.2002)
31. Conor Medsystems Inc., v. Angiotech Pharmaceuticals & Anr [2008] UKHL, 49 (09.07.2008)
32. Spenner J.M. Obvious-to-try. Obviousness of chemical enantiomers, in view of pre- and post-KSR analysis. J. Pat. & Trademark Off. Soc 90 (2008) 475-515
33. Hutt A.J. Drug chirality and its pharmacological consequences. In: Smith H.J. (Ed). Smith and Williams' Introduction to the Principles of Drug Design and Action. 4th edn (2006), CRC Press (Taylor & Francis) 117-183
34. Ariëns E.J. Stereochemistry, a basis for sophisticated nonsense in pharmacokinetics and clinical pharmacology. Eur. J. Clin. Pharmacol. 26 (1984) 663-668
35. Ariëns E.J. Stereochemistry: a source of problems in medicinal chemistry. Med. Chem. Res. 6 (1986) 451-466
36. Generics (UK) Limited v. Daiichi Pharmaceutical Co. Ltd and Anr [2008] EWHC 2413 (Pat) (15.10.2008)
37. Generics (UK) and Ors v. Lundbeck A/S [2008] EWHC 1040 (Pat) (04.05.2007)
38. Caner H., et al. Trends in the development of chiral drugs. Drug Discov. Today 9 (2004) 105-110
39. Center for Drugs and Biologics (1987) Guideline for submitting supporting documentation in drug applications for the manufacture of drug substances. Center for Drugs and Biologics, Food and Drug Administration, Department of Health and Human Services
40. Strong M. FDA policy and regulation of stereoisomers: paradigm shift and the future of safer, more effective drugs. Food Drug Law J. 54 (1999) 463-487
41. Lundbeck A/S v. Neolab and Ors, BGH Xa ZR 130/07 (10.09.2009)
42. In re Ciprofloxacin Hydrochloride Antitrust Litigation, CAFC 2008-1097 (15.10.2008); 544 F.3d 1323 (Fed. Cir. 2008)
43. Treacy P., and Hopson H. Patent settlements: will the European Commission follow in the FTC's footsteps...?. J. Intellect. Property Law & Pract. 3 (2008) 622-624
44. Shuchman M. Delaying generic competition - corporate payoffs and the future of Plavix. N. Engl. J. Med. 355 (2006) 1297-1300
45. Sanofi-Synthelabo Inc. et al. v. Apotex, Inc. et al. CAFC 06-1613 (08.12.06); 470 F. 3d 1368 (Fed. Cir. 2006)
46. Sanofi-Synthelabo, et al. v. Apotex Inc. US CAFC 2007-1438 (12.12.2008)
47. Agranat I., and Caner H. Intellectual property and chirality of drugs. Drug Discov. Today 4 (1999) 313-321
48. Ahner, F. and Boutaric, A. (2009) Enantiomers: revocation of a patent on enantiomer (-) for lack of enablement. Cabinet Regimbeau, Legal News, 22.10.2009, 1-4 (http://www.ragimbeau.com; file: 2009 10 22 COM Enantiomers FA and ANB.pdf)
49. Darrow J.J. The patentability of enantiomers: implications for the pharmaceutical industry. Stan. Tech. L. Rev. (2007) 2
50. Eisenberg R.S. Pharma's nonobvious problem. Lewis & Clark L. Rev. (2008) 375-429
51. Gorlin D.L. Staving off death: a case study of the pharmaceutical industry's strategies to protect blockbuster franchises. Food Drug Law J. 63 (2008) 823-864
52. Mansell, P. (2008) Who is afraid of the patent cliff? SCRIP Executive Briefing 1 No 6, 1-16
53. Generics (UK) Limited and Ors v. H. Lundbeck A/S [2009] UKHL 12; [2009] RPC 13 (25.02.2009)
54. Forest Laboratories, Inc., et al. v. Ivax Pharmaceuticals Inc., et al.; CAFC 2007-1059 (05.09.2007); 501 F. 3d 1263 (Fed. Cir. 2007)
55. Alphapharm Pty Ltd v. H. Lundbeck A/S [2008] Australia FCA 559 (24.04.2008)
56. Ranbaxy UK Limited & Anor v. Warner-Lambert Company [2005] EWHC 2142 (Patents) (12.10.2005)
57. Pfizer Inc., et al. v. Ranbaxy Laboratories Limited, et al. CAFC 2006-1179 (02.08.2006); 457 F. 3d 1284 (Fed. Cir. 2006)
58. Apotex Pty Ltd (formerly GenRx Pty Ltd) v. Sanofi-Aventis [2008] FCA 1194 (12.08.2008)
59. Apotex Pty Ltd v. Sanofi-Aventis [2009] FCAFC 134 (29.09.2009)
60. Ratiopharm GmbH v. AstraZeneca AB, (2006) EPO/TBA T 0401/04 (19.12.2006)
61. Novopharm Limited v. Janssen-Ortho Inc. & Anor 2007 FCA 217 (07.06.2007)